Cubist Pharmaceuticals, Inc. Reports GAAP Basic Net Income Of $0.10 Per Share In Fourth Quarter 2006 And GAAP Net Loss Of ($0.01) Per Share For Full Year 2006; 2006 Non-GAAP Diluted Income Of $0.28 Per Share

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported results for the fourth quarter and year ended December 31, 2006. Total net revenues for the fourth quarter of 2006 increased 53% year over year from $36.9 million in the fourth quarter of 2005 to $56.5 million in the fourth quarter of 2006. This increase was attributable primarily to net sales of CUBICIN® (daptomycin for injection) which increased 54% year over year from $36.6 million in the fourth quarter of 2005 to $56.4 million in the fourth quarter of 2006.